These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 18619059)

  • 21. Clinical use of interferon in hepatitis B and C.
    Schalm SW
    Verh K Acad Geneeskd Belg; 2009; 71(1-2):87-99. PubMed ID: 19739400
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Interferon therapy in chronic hepatitis B reduces progression to cirrhosis and hepatocellular carcinoma: a meta-analysis.
    Yang YF; Zhao W; Zhong YD; Xia HM; Shen L; Zhang N
    J Viral Hepat; 2009 Apr; 16(4):265-71. PubMed ID: 19220736
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Can infections protect against autoimmunity?
    Gaisford W; Cooke A
    Curr Opin Rheumatol; 2009 Jul; 21(4):391-6. PubMed ID: 19412105
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Impact of host insulin resistance on fibrosis and response to interferon in chronic hepatitis C.
    Moţa M; Popa S; Mota E; Diaconescu I; Gheorghiţoiu I; Panduru M
    Rom J Intern Med; 2008; 46(2):105-12. PubMed ID: 19284081
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The interferons: biological effects, mechanisms of action, and use in multiple sclerosis.
    Weinstock-Guttman B; Ransohoff RM; Kinkel RP; Rudick RA
    Ann Neurol; 1995 Jan; 37(1):7-15. PubMed ID: 7529476
    [No Abstract]   [Full Text] [Related]  

  • 26. [Recommendations from the GESIDA/Spanish AIDS Plan regarding antiretroviral treatment in adults with human immunodeficiency virus infection (update February 2009)].
    Panel de expertos de Gesida y Plan Nacional sobre el Sida
    Enferm Infecc Microbiol Clin; 2009 Apr; 27(4):222-35. PubMed ID: 19246124
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Interferons as antineoplastic drugs--direct regulatory effects on tumor cells].
    Kubes M
    Bratisl Lek Listy; 1993 Nov; 94(11):596-601. PubMed ID: 7522936
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Using a surveillance system to identify and treat newly acquired hepatitis C infection.
    Walsh N; Lim M; Hellard M
    J Gastroenterol Hepatol; 2008 Dec; 23(12):1891-4. PubMed ID: 19120877
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The effect of controlled therapy interruption in chronic HCV infection: enhanced host immune response? A hypothesis.
    Lake-Bakaar G
    J Clin Virol; 2009 Feb; 44(2):149-51. PubMed ID: 19157972
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Hepatitis C virus (HCV): a review of immunological aspects.
    Irshad M; Khushboo I; Singh S; Singh S
    Int Rev Immunol; 2008; 27(6):497-517. PubMed ID: 19065353
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The extrahepatic manifestations of hepatitis B virus.
    Baig S; Alamgir M
    J Coll Physicians Surg Pak; 2008 Jul; 18(7):451-7. PubMed ID: 18760074
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mathematical modeling of HCV infection and treatment.
    Dahari H; Shudo E; Ribeiro RM; Perelson AS
    Methods Mol Biol; 2009; 510():439-53. PubMed ID: 19009281
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Whole blood assessment of antigen specific cellular immune response by real time quantitative PCR: a versatile monitoring and discovery tool.
    Schultz-Thater E; Frey DM; Margelli D; Raafat N; Feder-Mengus C; Spagnoli GC; Zajac P
    J Transl Med; 2008 Oct; 6():58. PubMed ID: 18925935
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Chronic viral hepatitis may diminish the gains of HIV antiretroviral therapy in sub-Saharan Africa.
    Cooper CL; Mills E; Wabwire BO; Ford N; Olupot-Olupot P
    Int J Infect Dis; 2009 May; 13(3):302-6. PubMed ID: 19004656
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Characteristics and outcome of patients with dual hepatitis B and C-associated hepatocellular carcinoma: are they different from patients with single virus infection?
    Huo TI; Huang YH; Hsia CY; Su CW; Lin HC; Hsu CY; Lee PC; Lui WY; Loong CC; Chiang JH; Chiou YY; Lee SD
    Liver Int; 2009 May; 29(5):767-73. PubMed ID: 19018974
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Innate immune response to viral infection.
    Koyama S; Ishii KJ; Coban C; Akira S
    Cytokine; 2008 Sep; 43(3):336-41. PubMed ID: 18694646
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Preventing and curing multiple sclerosis by controlling Epstein-Barr virus infection.
    Pender MP
    Autoimmun Rev; 2009 Jun; 8(7):563-8. PubMed ID: 19254880
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Incidence, risk factors, and outcome of chronic rejection during antiviral therapy for posttransplant recurrent hepatitis C.
    Fernández I; Ulloa E; Colina F; Abradelo M; Jiménez C; Gimeno A; Meneu JC; Lumbreras C; Solís-Herruzo JA; Moreno E
    Liver Transpl; 2009 Aug; 15(8):948-55. PubMed ID: 19642125
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Chronic hepatitis C and persistent occult hepatitis C virus infection are characterized by distinct immune cell cytokine expression profiles.
    Pham TN; Mercer SE; Michalak TI
    J Viral Hepat; 2009 Aug; 16(8):547-56. PubMed ID: 19215578
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immunotherapy for HCV infection: next steps.
    Lang K; Weiner DB
    Expert Rev Vaccines; 2008 Sep; 7(7):915-23. PubMed ID: 18767942
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.